EUCTR2010-019249-25-DE进行中（未招募）不适用
An open, prospective trial investigating pharmacokinetics and safety (Part A) of the human normal immunoglobulin for intravenous infusion (IVIG) BT090 and tolerability and safety of escalating infusion rates (Part B) in patients with primary immunodeficiency disease (PID)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Biotest AG
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female patients (age 6–65 years)
- •- Diagnosis of common variable immunodeficiency (CVID) or X-linked agammaglobulinemia (XLA) as defined by ESID/PAGID diagnostic criteria
- •- Written informed consent
- •- Established replacement therapy with any IVIG reference preparation during the previous 6 months, including documentation of IgG trough levels
- •- Established replacement therapy with a single IVIG reference preparation for at least 3 months prior to treatment start with BT090, with constant IVIG dose that had not changed by ± 50% of the mean dose as well as dosage interval for at least 3 months prior to study entry and had maintained IgG trough levels of = 6g/L
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Pregnancy or unreliable contraceptive measures or lactation period (women only)
- •- Known intolerance to immunoglobulins or comparable substances (e.g. vaccination reaction)
- •- Known intolerance to proteins of human origin
- •- Participation in another clinical trial within 90 days before entering the trial or during the trial and/or previous participation in this trial
- •- Inability or lacking motivation to participate in the trial
- •- Selective, absolute IgA deficiency or known antibodies to IgA
- •- Positive diagnostics of hepatitis B and hepatitis C
- •- Positive HIV test
- •- Acquired medical condition known to cause secondary immune deficiency such as CLL, lymphoma, multiple myeloma
- •- Patients with protein losing enteropathies, hypoalbuminaemia
研究者
相似试验
进行中（未招募）
不适用
Eine offene, prospektive Studie zur Untersuchung der Pharmakokinetikund Sicherheit (Teil A) des Immunglobulins vom Menschen zurintravenösen Infusion (IVIG) BT090 sowie der Verträglichkeit undSicherheit von steigenden Infusionsgeschwindigkeiten (Teil B) beiPatienten mit primären Immundefekten (PID)Primary immunodeficiency disease (PID)MedDRA version: 13.1Level: LLTClassification code 10010509Term: Congenital hypogammaglobulinemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2010-019249-25-HUBiotest AG30
进行中（未招募）
不适用
A Phase I, open-label trial to investigate pharmacokinetics, safetyand tolerability of TMC125 at steady-state in treatment-experiencedHIV-1 infected children.HIV-1MedDRA version: 8.1Level: LLTClassification code 10020192Term: HIV-1EUCTR2006-002183-26-DETibotec Pharmaceuticals Ltd40
进行中（未招募）
1 期
A Phase I, open-label trial to investigate pharmacokinetics, safety and tolerability of TMC125 at steady-state in treatment-experienced HIV-1 infected children.EUCTR2006-002183-26-GBTibotec Pharmaceuticals Ltd42
进行中（未招募）
1 期
An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 diseaseCOVID-19-associated diseaseEUCTR2020-001754-21-FRAssistance Publique Hôpitaux de Marseille150
进行中（未招募）
1 期
Drug metabolism related to obesityMedDRA version: 19.1Level: LLTClassification code 10029885Term: Obesity, unspecifiedSystem Organ Class: 100000004861EUCTR2014-004554-34-DKBispebjerg Hospital